

4 November 2011

The Manager
 Company Announcements Office
 ASX Limited
 20 Bridge St
 SYDNEY NSW 2000

Dear Sir

RESULTS OF GENERAL MEETING

We wish to advise that resolutions put to the General Meeting of CBio Limited held today were each passed on a show of hands.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution as follows:-

	For the resolution	At proxy's discretion	Against resolution	Abstain from resolution
Resolution 1				
Withdrawn	-	-	-	-
Resolution 2				
Withdrawn	-	-	-	-
Resolution 3				
Withdrawn	-	-	-	-
Resolution 4				
Appointment of Helen Cameron as a Director	107,897,569	1,348,772	38,611,582	10,141
Resolution 5				
Appointment of Ralph Craven as a Director	108,957,900	1,348,772	37,545,251	16,141
Resolution 6				
Appointment of Warren Brown as a Director	108,763,700	1,348,772	37,674,613	80,979

For and on behalf of the Board of CBio Limited

Roslynn Shand
 Company Secretary

About CBio Limited

CBio is an Australian ASX listed company established in 2000. CBio's lead product XToll is a potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis (RA) and lupus.

Enquiries

Melanie Farris
Communications and Corporate Affairs Manager
CBio Limited
T: +61 (0)449 148 448
melanie.farris@cbio.com.au